<DOC>
	<DOCNO>NCT01619839</DOCNO>
	<brief_summary>NKTR-181 develop analgesic compound treatment moderate severe chronic pain - active mu agonist , inherent molecular property design provide unique clinical profile , include notably , reduce CNS side effect attenuate attractiveness target abuse .</brief_summary>
	<brief_title>A Phase 2 Study To Assess The Efficacy , Tolerability , And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Willing able give write informed consent ; Willing able understand study procedure , comply study procedure ; Females male , age â‰¥ 18 year old ; Body mass index 1839 , inclusive ; In good general health ; Clinical diagnosis OA one knees ; Have stable regimen pain medication management OA knee pain ; Not experience adequate pain relief current dose regimen ; Women childbearing potential ( WCBP ) must agree use highly effective method birth control . Male subject must agree use contraception . Females pregnant lactating ; Known history hypersensitivity , intolerance , allergy opioids ; Diagnosed chronic pain symptom Investigator 's opinion would interfere assessment pain symptom OA ; Presence medical condition would preclude study participation opinion investigator ; Clinically significant abnormality vital sign clinical laboratory result ; Clinically significant electrocardiographic abnormality ; Received systemic corticosteroid within 30 day prior sign consent form ; Subjects know suspect currently abuse alcohol drug ; Positive urine drug screen , alcohol breath test Screening Period test ; Positive serology surface antigen Hepatitis B ( HBsAg ) Hepatitis C ( antiHCV ) Screening Period testing ; Known human immunodeficiency virus ( HIV ) positive ; Donation blood plasma within 30 day prior sign consent form ; Participation another drug biologic study within 30 day prior sign consent form ; Any reason , opinion Investigator Medical Monitor , would render subject unsuitable participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Nektar</keyword>
	<keyword>NKTR-181</keyword>
</DOC>